Cat. No.: HY-15251

Reparixin

(Synonyms: Repertaxin; DF 1681Y)

63 Cited Publications

Avis client

Based on 63 publication(s) in Google Scholar

Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC₅₀s of 1 and 100 nM, respectively.

Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.

Pureté: 99.99%
CAS No.: 266359-83-5
Formule: C₁₄H₂₁NO₃S
Masse moléculaire:283.39

Stockage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year

Reparixin Chemical Structure

CAS No.: 266359-83-5

Size

Prix

Stock

Quantité

Amount: USD 0.00

* Veuillez sélectionner la quantité avant d'ajouter des articles.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Activité biologique
- Description
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
- Essai clinique
Chemical Information
Publications (63)
Solvant et solubilité
- In Vitro
- In Vivo
Protocole
Pureté et documentation
Références
Help & FAQs
Classifications
Bioz

Activité biologique

Description

Reparixin is a non-competitive allosteric inhibitor of the chemokine receptors CXCR1 and CXCR2 activation with IC₅₀s of 1 and 100 nM, respectively.

IC₅₀ & Target^[1]^[5]

CXCR1^wt

5.6 nM (IC₅₀, in L1.2 cells)

CXCR1^Ile43Val

80 nM (IC₅₀, in L1.2 cells)

CXCR1

1 nM (IC₅₀, in cells)

CXCR2

∼100 nM (IC₅₀, in cells)

Voir tous les produits spécifiques à Isoform CXCR :

Cellular Effect

Cell Line	Type	Value	Description	References
L1.2	IC₅₀	0.0056 μM Compound: raparixin	Inhibition of CXCL8-induced cell migration in L1.2 cells expressing CXCR1 by chemotaxis assay Inhibition of CXCL8-induced cell migration in L1.2 cells expressing CXCR1 by chemotaxis assay	[PMID: 17665889]
L1.2	IC₅₀	0.08 μM Compound: raparixin	Inhibition of CXCL8-induced cell migration in L1.2 cells expressing Ile43Val CXCR1 mutant by chemotaxis assay Inhibition of CXCL8-induced cell migration in L1.2 cells expressing Ile43Val CXCR1 mutant by chemotaxis assay	[PMID: 17665889]

In Vitro

Reparixin is a potent functional inhibitor of CXCL8-induced biological activities on human PMNs with a marked selectivity (around 400-fold) for CXCR1, as shown in specific experiments on CXCR1/L1.2 and CXCR2/L1.2 transfected cells and on human PMNs. The efficacy of Reparixin is significantly lower in L1.2 cells expressing Ile43Val CXCR1 mutant (IC₅₀ values of 5.6 nM and 80 nM for CXCR1 wt and CXCR1 Ile43Val, respectively)^[1]. Reparixin is a non-competitive allosteric inhibitor of IL-8 receptors with a 400-fold higher efficacy in inhibiting CXCR1 activity than CXCR2^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

Reparixin is an inhibitor of CXCL8 receptor CXCR1 and CXCR2 activation, has been shown to attenuate inflammatory responses in various injury models. Spontaneously hypertensive rats (SHR) are administered a subcutaneous injection of Reparixin (5 mg/kg) daily for 3 weeks. Reparixin effectively decreases systolic blood pressure and increased the blood flow^[3]. Reparixin reduces the levels of IL-1β in the brain after middle cerebral artery occlusion/reperfusion (MCAo) in mice. Bars represent levels of IL-1β (pg/100 mg) measured by ELISA in the brain tissues of mice subjected or not (SHAM) to MCAo and pretreated with vehicle or Reparixin (30 mg/kg, s.c.)^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Essai clinique

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS No. 266359-83-5
Appearance Solid
Masse moléculaire 283.39
Formule C₁₄H₂₁NO₃S
Color White to off-white
SMILES

CS(=O)(NC([C@@H](C1=CC=C(CC(C)C)C=C1)C)=O)=O
Synonyms

Repertaxin; DF 1681Y
Livraison

Room temperature in continental US; may vary elsewhere.

Stockage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Publications (63)

All Cell Proliferation/Viability AssayIF

Sort by:

Journal Impact Factor

Science

A genetically encoded device for transcriptome storage in mammalian cells. [Abstract]

2026 Mar 26;391(6792):eadz9353. PMID: 41538410
Cancer Cell

Neutralizing IL-8 potentiates immune checkpoint blockade efficacy for glioma. [Abstract]

2023 Apr 10;41(4):693-710.e8. PMID: 36963400
Ann Rheum Dis

Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. [Abstract]

2016 Apr;75(4):721-9. PMID: 26612338
Ann Rheum Dis

Autoantibodies to citrullinated proteins induce joint pain independent of inflammation via a chemokine-dependent mechanism. [Abstract]

2016 Apr;75(4):730-8. PMID: 26613766
Nat Commun

Synergistic IL-6 and IL-8 paracrine signalling pathway infers a strategy to inhibit tumour cell migration. [Abstract]

2017 May 26;8:15584. PMID: 28548090
Adv Sci (Weinh)

Single-Cell Landscape of Bronchoalveolar Lavage Fluid Identifies Specific Neutrophils during Septic Immunosuppression. [Abstract]

2025 Jan 30:e2406218. PMID: 39887584
Adv Sci (Weinh)

SKAP1 Expression in Cancer Cells Enhances Colon Tumor Growth and Impairs Cytotoxic Immunity by Promoting Neutrophil Extracellular Trap Formation via the NFATc1/CXCL8 Axis. [Abstract]

2024 Sep 13:e2403430. PMID: 39269257
Sci Adv

Differentiated fibrocytes assume a functional mesenchymal phenotype with regenerative potential. [Abstract]

2019 May 8;5(5):eaav7384. PMID: 31086819
J Biomed Sci

Fusobacterium nucleatum promotes colorectal cancer liver metastasis via miR-5692a/IL-8 axis by inducing epithelial-mesenchymal transition. [Abstract]

2025 Jan 6;32(1):5. PMID: 39757156
Mol Ther

Engineered bispecific antibodies targeting the interleukin-6 and -8 receptors potently inhibit cancer cell migration and tumor metastasis. [Abstract]

2022 Nov 2;30(11):3430-3449. PMID: 35841152
J Allergy Clin Immunol

Human TH17 cell development requires processing of dendritic cell-derived CXCL8 by neutrophil elastase. [Abstract]

2018 Jun;141(6):2286-2289.e5. PMID: 29391256
EBioMedicine

Interleukin-8 as a therapeutic target for chronic low back pain: Upregulation in human cerebrospinal fluid and pre-clinical validation with chronic reparixin in the SPARC-null mouse model. [Abstract]

2019 May:43:487-500. PMID: 31047862
Cancer Lett

DysUFMylation reprograms immunosuppressive neutrophils to potentiate anti-PD-1 therapy in hepatocellular carcinoma. [Abstract]

2026 May 1:645:218395. PMID: 41780840
Mol Biomed

C-X-C motif chemokine ligand 1 derived from oral squamous cell carcinoma promotes cancer-associated fibroblast differentiation and tumor growth. [Abstract]

2025 Jun 10;6(1):40. PMID: 40490643
Cell Death Dis

An autocrine inflammatory forward-feedback loop after chemotherapy withdrawal facilitates the repopulation of drug-resistant breast cancer cells. [Abstract]

2017 Jul 13;8(7):e2932. PMID: 28703802
Cell Commun Signal

Paracrine secretion of IL8 by breast cancer stem cells promotes therapeutic resistance and metastasis of the bulk tumor cells. [Abstract]

2023 Mar 13;21(1):59. PMID: 36915147
Dev Cell

MITA/STING-driven CD38 induction in Siglec-Flow macrophages promotes regulatory T cell survival and non-small cell lung cancer progression. [Abstract]

2026 Jan 12:S1534-5807(25)00768-3. PMID: 41529690
BMC Med

Upregulation of NOD1 and NOD2 contribute to cancer progression through the positive regulation of tumorigenicity and metastasis in human squamous cervical cancer. [Abstract]

2022 Feb 8;20(1):55. PMID: 35130902
Cell Mol Gastroenterol Hepatol

Concomitant NAFLD Facilitates Liver Metastases and PD-1-Refractory by Recruiting MDSCs via CXCL5/CXCR2 in Colorectal Cancer. [Abstract]

2024 May 7:S2352-345X(24)00105-X. PMID: 38724007
Int Endod J

The Interplay of M1 Macrophages and Dental Pulp Stem Cells Promotes Angiogenesis Through IL-8-Dependent VEGF Regulation: An In Vitro Study. [Abstract]

2026 Jun 24. PMID: 42339579
Oncogenesis

Loss of OLFM4 promotes tumor migration through inducing interleukin-8 expression and predicts lymph node metastasis in early gastric cancer. [Abstract]

2016 Jun 13;5(6):e234. PMID: 27294866

Reparixin purchased from MedChemExpress. Usage Cited in: Oncogenesis. 2016 Jun 13;5(6):e234. [Abstract]

The effects of Reparixin (100 nM) on the migration of OLFM4-depleted gastric cancer cells are detected by transwell assay.
Brain Pathol

Intracerebellar administration of the chemokine Cxcl3 reduces the volume of medulloblastoma lesions at an advanced stage by promoting the migration and differentiation of preneoplastic precursor cells. [Abstract]

2024 Jun 30:e13283. PMID: 38946128
Cell Biosci

1-Palmitoyl-2-linoleoyl-3-acetyl-rac-glycerol (PLAG) attenuates gemcitabine-induced neutrophil extravasation. [Abstract]

2019 Jan 3:9:4. PMID: 30622698
Cancer Cell Int

SHP2 inhibition enhances the anticancer effect of Osimertinib in EGFR T790M mutant lung adenocarcinoma by blocking CXCL8 loop mediated stemness. [Abstract]

2021 Jul 3;21(1):337. PMID: 34217295
J Mol Cell Biol

CSF2 upregulates CXCL3 expression in adipocytes to promote metastasis of breast cancer via the FAK signaling pathway. [Abstract]

2023 Aug 3;15(4):mjad025. PMID: 37073091
Front Immunol

CXCR1 and its downstream NF-κB inflammation signaling pathway as a key target of Guanxinning injection for myocardial ischemia/reperfusion injury. [Abstract]

2022 Oct 17:13:1007341. PMID: 36325326

Reparixin purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 Oct 17:13:1007341. [Abstract]

In HL-1 cells, when DSS and Reparixin (100nM) are applied in combination, the high expression levels of NF-κB, COX-2, ICAM-1 and VCAM-1 induced by OGD/R are further inhibited compared with that of DSS alone.
Front Immunol

CXCL8 Associated Dendritic Cell Activation Marker Expression and Recruitment as Indicators of Favorable Outcomes in Colorectal Cancer. [Abstract]

2021 May 7;12:667177. PMID: 34025668
Front Immunol

Amphibian ( Xenopus laevis) Interleukin-8 (CXCL8): A Perspective on the Evolutionary Divergence of Granulocyte Chemotaxis. [Abstract]

2018 Sep 12:9:2058. PMID: 30258441
Neurobiol Dis

CXCR2 increases in ALS cortical neurons and its inhibition prevents motor neuron degeneration in vitro and improves neuromuscular function in SOD1G93A mice. [Abstract]

2021 Dec:160:105538. PMID: 34743985
Cells

FRY Mediates THP1-Driven Ovarian Cancer Invasion Through the PI3K/AKT Pathway. [Abstract]

2026 Feb 3;15(3):289. PMID: 41677651
Cells

The AGEs/RAGE Transduction Signaling Prompts IL-8/CXCR1/2-Mediated Interaction between Cancer-Associated Fibroblasts (CAFs) and Breast Cancer Cells. [Abstract]

2022 Aug 4;11(15):2402. PMID: 35954247
Cells

A Therapeutic Whole-Tumor-Cell Vaccine Covalently Conjugated with a TLR7 Agonist. [Abstract]

2022 Jun 21;11(13):1986. PMID: 35805071
Cancers (Basel)

Novel Function of Cancer Stem Cell Marker ALDH1A3 in Glioblastoma: Pro-Angiogenesis through Paracrine PAI-1 and IL-8. [Abstract]

2023 Sep 4;15(17):4422. PMID: 37686698
J Cell Mol Med

Neuropilin-1 is up-regulated by cancer-associated fibroblast-secreted IL-8 and associated with cell proliferation of gallbladder cancer. [Abstract]

2020 Nov;24(21):12608-12618. PMID: 32951327
J Cell Mol Med

IL-8 promotes cell migration through regulating EMT by activating the Wnt/β-catenin pathway in ovarian cancer. [Abstract]

2020 Jan;24(2):1588-1598. PMID: 31793192
J Mol Med (Berl)

Propionibacterium acnes induces discogenic low back pain via stimulating nucleus pulposus cells to secrete pro-algesic factor of IL-8/CINC-1 through TLR2-NF-κB p65 pathway. [Abstract]

2019 Jan;97(1):25-35. PMID: 30397790
Biochim Biophys Acta

The matrikine N-acetylated proline-glycine-proline induces premature senescence of nucleus pulposus cells via CXCR1-dependent ROS accumulation and DNA damage and reinforces the destructive effect of these cells on homeostasis of intervertebral discs. [Abstract]

2017 Jan;1863(1):220-230. PMID: 27769935
Xenotransplantation

Interleukin-8 mediates neutrophil-endothelial interactions in pig-to-human xenogeneic models. [Abstract]

2018 Mar;25(2):e12385. PMID: 29427404
Sci Rep

Protein profiling identified key chemokines that regulate the maintenance of human pluripotent stem cells. [Abstract]

2017 Nov 6;7(1):14510. PMID: 29109449
Brain Res Bull

Multi-omics analysis reveals the protective role of transcriptional enhancer factor and the pathogenic mechanism of monocytes in Parkinson's disease. [Abstract]

2025 Oct 22:232:111594. PMID: 41135742
Stem Cells

Collagen-Derived N-Acetylated Proline-Glycine-Proline in Intervertebral Discs Modulates CXCR1/2 Expression and Activation in Cartilage Endplate Stem Cells to Induce Migration and Differentiation Toward a Pro-Inflammatory Phenotype. [Abstract]

2015 Dec;33(12):3558-68. PMID: 26302999
J Immunol

Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. [Abstract]

2018 Jul 15;201(2):814-820. PMID: 29802127
J Gastroenterol Hepatol

High expression of tumor necrosis factor receptor-associated factor 2 promotes tumor metastasis and is associated with unfavorable prognosis in gastric cancer. [Abstract]

2018 Feb;33(2):431-442. PMID: 28482378

Reparixin purchased from MedChemExpress. Usage Cited in: J Gastroenterol Hepatol. 2018 Feb;33(2):431-442. [Abstract]

The effects of TRAF2 overexpression with or without Reparixin (100 nM), or BAY 11-7082 (30 μM) on the migration and invasion of AGS cell are examined by transwell assay.
Mol Immunol

Interleukin 8 (CXCL8)-CXC chemokine receptor 2 (CXCR2) axis contributes to MiR-4437-associated recruitment of granulocytes and natural killer cells in ischemic stroke. [Abstract]

2018 Sep:101:440-449. PMID: 30096583
FACETS

2020 Jul.
Gene

Conserved structure and function of chemokine CXCL8 between Chinese tree shrews and humans. [Abstract]

2018 Nov 30:677:149-162. PMID: 30012425
Biomed Res Int

Icariin Ameliorates Lower Back Pain in Rats via Suppressing the Secretion of Cytokine-Induced Neutrophil Chemoatractant-1. [Abstract]

2020 Aug 5;2020:4670604. PMID: 32802846
Vet Immunol Immunopathol

CC chemokine ligand 2 and CXC chemokine ligand 8 as neutrophil chemoattractant factors in canine idiopathic polyarthritis. [Abstract]

2016 Dec:182:52-58. PMID: 27863550
bioRxiv

Respiratory viral infections prime accelerated lung cancer growth. [Abstract]

2025 Sep 3:2025.09.02.672566. PMID: 40950232
bioRxiv

Mast cells interact directly with colorectal cancer cells to promote epithelial-to-mesenchymal transition. [Abstract]

2025 Mar 19:2025.03.19.644113. PMID: 40166179
Patent

US20240295544A1.
bioRxiv

Chemokine expression profile of an innate granuloma. [Abstract]

2024 Jun 6:2024.01.30.577927. PMID: 38352492
Patent

US20220251222A1.
Karolinska Institutet

2022 Feb.
Int J Biol Sci

Cancer-associated adipocytes promote the invasion and metastasis in breast cancer through LIF/CXCLs positive feedback loop. [Abstract]

2022 Jan 16;18(4):1363-1380. PMID: 35280694
Research Square Preprint

2021 Mar.
bioRxiv

SARS-CoV-2 infection of human iPSC-derived cardiac cells predicts novel cytopathic features in hearts of COVID-19 patients. [Abstract]

2020 Sep 12:2020.08.25.265561. PMID: 32935097
University of Michigan

2018 Oct.
Oncotarget

Tumor cell density regulates matrix metalloproteinases for enhanced migration. [Abstract]

2018 Aug 24;9(66):32556-32569. PMID: 30220965
Oncotarget

Crosstalk between stromal components and tumor cells of TNBC via secreted factors enhances tumor growth and metastasis. [Abstract]

2017 Jul 21;8(36):60210-60222. PMID: 28947965

Reparixin purchased from MedChemExpress. Usage Cited in: Oncotarget. 2017 Jul 21;8(36):60210-60222. [Abstract]

Migration assay of MDA-MB-231 cells treated 0.1 uM of Reparixin in CM from fibroblasts or macrophages with TCM of MDA-MB-231 cells using the Oris Cell migration kit.
Patent

US20170181987A1.
Patent

US20170105971A1.
Johns Hopkins University

2016 Dec.

Solvant et solubilité

In Vitro:

DMSO : ≥ 100 mg/mL (352.87 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : < 0.1 mg/mL (insoluble)

* "≥" means soluble, but saturation unknown.

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.5287 mL

17.6435 mL

35.2871 mL

5 mM

0.7057 mL

3.5287 mL

7.0574 mL

10 mM

0.3529 mL

1.7644 mL

3.5287 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Calculateur de molarité

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Calculateur de dilution

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

Protocol 4

Add each solvent one by one: 5% DMSO 40% PEG300 5% Tween-80 50% Saline

Solubility: ≥ 2.5 mg/mL (8.82 mM); Clear solution

Protocol 5

Add each solvent one by one: 5% DMSO 95% (20% SBE-β-CD in Saline)

Solubility: 2.5 mg/mL (8.82 mM); Suspended solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Protocole

Cell Assay^[1]

L1.2 Cell suspension (1.5-3×10⁶ cells/mL) is incubated at 37°C for 15 min in the presence of vehicle or of Reparixin (1 nM-1μM) and next seeded in triplicates in the upper compartment of the chemotactic chamber. Different agonists are seeded in the lower compartment of the chamber at the following concentrations: 1 nM CXCL8, 0.03 nM fMLP, 10 nM CXCL1, 2.5 nM CCL2, 30 nM C5a. The chemotactic chamber is incubated at 37°C in air with 5% CO₂ for 45 min (human PMNs) or 2 h (monocytes). At the end of incubation, the filter is removed, fixed, and stained and five oil immersion fields at high magnification (100×) are counted for each migration well after sample coding. L1.2 migration is evaluated using 5 μm pore size Transwell filters^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Administration^[3]^[4]

Rats^[3]
The Reparixin-treated group contained 5 SHR (SHR-R), where equal numbers of normal saline-treated SHR (SHR-N) and WKY (WKY-N) served as controls. Eighteen-week-old SHR received a subcutaneous injection of Reparixin (5 mg/kg) once per day for 3 weeks. Reparixin effects on blood flow, blood pressure and body weight are measured before treatment and then weekly until 1 week after the final injection. The effect of Reparixin on the expression of hypertension-related mediators in thoracic aortas, as well as nitric oxide (NO) plasma levels, is examined 1 week after the final injection.
Mice^[4]
C57BL/6J mice (8-10 weeks old/20-25 g) are used. The subcutaneous administration of Reparixin (30 mg/kg) is performed 60 minutes before cerebral ischemia induction. The animals are divided into the following three experimental groups: Sham (i.e., the group in which the arteries are visualized, but there is no occlusion of the middle cerebral artery), Vehicle (i.e., the group pre-treated with the vehicle, phosphate buffer solution, 60 minutes before MCAo) and Reparixin (i.e., the group pre-treated with the drug 60 minutes before MCAo). To evaluate neurological signs secondary to MCAo, the animals are assessed with the SHIRPA battery 24 h after reperfusion.

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Pureté et documentation

Select Batch:

Pureté: 99.98%

Assay: 99.98%

ee.: 99.98%

Fiche technique (281 KB)
SDS (396 KB)
- English - EN (396 KB)
- Français - FR (396 KB)
- Deutsch - DE (396 KB)
- Norwegian - NO (396 KB)
- Español - ES (396 KB)
- Swedish - SV (396 KB)
- Italian - IT (396 KB)
- Korean - KR (396 KB)
- Portuguese - PT (396 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Instruction de manipulation (2659 KB)

Références

[1]. Moriconi A, et al. Design of noncompetitive interleukin-8 inhibitors acting on CXCR1 and CXCR2. J Med Chem. 2007 Aug 23;50(17):3984-4002. [Content Brief]

[2]. Bertini R, et al. Receptor binding mode and pharmacological characterization of a potent and selective dual CXCR1/CXCR2non-competitive allosteric inhibitor. Br J Pharmacol. 2012 Jan;165(2):436-54. [Content Brief]

[3]. Kim HY, et al. Reparixin, an inhibitor of CXCR1 and CXCR2 receptor activation, attenuates blood pressure and hypertension-related mediators expression in spontaneously hypertensive rats. Biol Pharm Bull. 2011;34(1):120-7. [Content Brief]

[4]. Sousa LF, et al. Blockade of CXCR1/2 chemokine receptors protects against brain damage in ischemic stroke in mice. Clinics (Sao Paulo). 2013;68(3):391-4. [Content Brief]

[5]. Bertini R, et al. Noncompetitive allosteric inhibitors of the inflammatory chemokine receptors CXCR1 and CXCR2: prevention of reperfusion injury. Proc Natl Acad Sci U S A. 2004 Aug 10;101(32):11791-6. [Content Brief]

[6]. Krishnamurthy A, et al. Identification of a novel chemokine-dependent molecular mechanism underlying rheumatoid arthritis-associated autoantibody-mediated bone loss. Ann Rheum Dis. 2016 Apr;75(4):721-9. [Content Brief]

[7]. Crespo J, et al. Human Naive T Cells Express Functional CXCL8 and Promote Tumorigenesis. J Immunol. 2018 Jul 15;201(2):814-820. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.5287 mL	17.6435 mL	35.2871 mL	88.2176 mL
	5 mM	0.7057 mL	3.5287 mL	7.0574 mL	17.6435 mL
	10 mM	0.3529 mL	1.7644 mL	3.5287 mL	8.8218 mL
	15 mM	0.2352 mL	1.1762 mL	2.3525 mL	5.8812 mL
	20 mM	0.1764 mL	0.8822 mL	1.7644 mL	4.4109 mL
	25 mM	0.1411 mL	0.7057 mL	1.4115 mL	3.5287 mL
	30 mM	0.1176 mL	0.5881 mL	1.1762 mL	2.9406 mL
	40 mM	0.0882 mL	0.4411 mL	0.8822 mL	2.2054 mL
	50 mM	0.0706 mL	0.3529 mL	0.7057 mL	1.7644 mL
	60 mM	0.0588 mL	0.2941 mL	0.5881 mL	1.4703 mL
	80 mM	0.0441 mL	0.2205 mL	0.4411 mL	1.1027 mL
	100 mM	0.0353 mL	0.1764 mL	0.3529 mL	0.8822 mL

Keywords

Reparixin

63 Cited Publications

100 mg Obtenir un devis

Subscribe to the

MedChemExpress

Newsletter

Nom du produit:
Cat. No.:
Quantité:
MCE Japan Authorized Agent:

Nom du produit:
CAS No.:
Species:
Pureté:
Quantité:

Reparixin

GPCR/G Protein Compound Library

Immunology/Inflammation Compound Library

Anti-Cancer Compound Library

Clinical Compound Library

Small Molecule Immuno-Oncology Compound Library

Drug Repurposing Compound Library

Endocrinology Compound Library

Pyroptosis Compound Library

Orally Active Compound Library

Anti-Pancreatic Cancer Compound Library

Targeted Diversity Library

Rare Diseases Drug Library

Human Metabolite Library

Chemokine Compound Library

Membrane Protein-targeted Compound Library

Membrane Receptor-targeted Compound Library

Highly Selective Inhibitors Library

Cytokine Inhibitors Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Drug Repurposing Compound Library Plus

Clinical Compound Library Plus

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Reparixin

Voir tous les produits spécifiques à Isoform CXCR

Activité biologique

Chemical Information

Publications (63)

Solvant et solubilité

Protocole

Pureté et documentation

Références

Help & FAQs

Complete Stock Solution Preparation Table

Reparixin Related Classifications

HY-15251 Related Classifications